RxDoctor Payments Data

Rupalini Rawal-Dhingra, MD

Obstetrics & Gynecology · Bristol, CTNPI 1588971998

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (53.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Intuitive Surgical at 54.0% of the total. Reporting peaked in 2022 at $3,393 and has fallen 92.0% since, to $270 in 2025. Among obstetrics & gynecology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,665in general payments, 2019–2025

Across 128 payments — averaging $44.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • AbbVie$419
  • Astellas Pharma US Inc$416
  • Therapeuticsmd, Inc.$184
  • Bayer$177
  • Pfizer$138
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,65047%
  • Education$150%
  • Other$3,00053%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,665 in reported general payments places this provider in the 90th percentile of 605 obstetrics & gynecology providers in Connecticut.

See all obstetrics & gynecology providers in Connecticut

Medicare billing

Part B allowed, 2024
$2,931
Medicare patients
35
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxybutynin Chloride ErOxybutynin Chloride18$340
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip20$334
Estradiol17$333
Alendronate Sodium17$148

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →